Alpelisib: all 81 studies that test it
Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Alpelisib Challenge Test (ACT)RecruitingNCT07778524Phase 1
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingNCT07679269Phase 2
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsRecruitingNCT07543822Phase 2
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)RecruitingNCT06997588Phase 2
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingNCT06545682Phase 1
- Human Models of Selective Insulin Resistance: Alpelisib, Part IRecruitingNCT06354088Phase 1
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingNCT05983159Phase 2
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.RecruitingNCT05948943Phase 2/3
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2
- Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)RecruitingNCT05577754Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasRecruitingNCT03631953Phase 1
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast CancerTerminatedNCT05966584Phase 2Results posted
- Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine TreatmentCompletedNCT05631795Phase 4Results posted
- Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerCompletedNCT05101564Phase 2Results posted
- Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantTerminatedNCT04862143Phase 2Results posted
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedNCT04729387Phase 3Results posted
- Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive, not recruitingNCT04589650Phase 2Results posted
- Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossTerminatedNCT04251533Phase 3Results posted
- Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsTerminatedNCT04216472Phase 2Results posted
- Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal CancerTerminatedNCT03601507Phase 2Results posted
- Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results posted
- BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group StudyTerminatedNCT02550743Phase 1Results posted
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedNCT02437318Phase 3Results posted
- BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast CancerCompletedNCT02379247Phase 1/2Results posted
- A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
- BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane TxCompletedNCT02038010Phase 1Results posted
- Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal WomenCompletedNCT01923168Phase 2Results posted
- Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal CancerCompletedNCT01719380Phase 2Results posted
- A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid TumorsTerminatedNCT01708161Phase 1/2Results posted
- A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT01602315Phase 1/2Results posted
- Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnNCT05967286Phase 2
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2
- Effect of Alpelisib in Healthy VolunteersCompletedNCT05733455Phase 1
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedNCT05625087Phase 2
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingNCT05508906Phase 1
- Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell CarcinomaWithdrawnNCT05472220Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2
- Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingNCT05143229Phase 1
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3
- Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingNCT05038735Phase 3
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedNCT04997902Phase 1/2
- Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active, not recruitingNCT04980833Phase 2
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast CancerActive, not recruitingNCT04762979Phase 2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04544189Phase 2
- Alpelisib and Paclitaxel in PIK3CA-altered Gastric CancerStatus unknownNCT04526470Phase 1/2
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04524000Phase 2
- Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationActive, not recruitingNCT04208178Phase 3
- SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast CancerTerminatedNCT03386162Phase 2
- Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2
- Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast CancerCompletedNCT03207529Phase 1
- A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719CompletedNCT03138070Not applicable
- Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersTerminatedNCT02734615Phase 1
- Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.CompletedNCT02624557Phase 1
- Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor MalignanciesTerminatedNCT02620839Phase 1
- Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck CancerCompletedNCT02537223Phase 1
- Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast CancerCompletedNCT02506556Phase 2
- Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell CarcinomaWithdrawnNCT02298595Phase 1/2
- Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)CompletedNCT02282371Phase 1
- Trial of AEB071 in Combination With BYL719 in Patients With MelanomaCompletedNCT02273219Phase 1
- Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerCompletedNCT02167854Phase 1
- BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic CancerCompletedNCT02155088Phase 1
- An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.Status unknownNCT02145312Phase 2
- Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT02144038Phase 1
- Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerCompletedNCT02088684Phase 1
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT02058381Phase 1
- A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck CancerCompletedNCT02051751Phase 1
- Phase 1b Trial of BGJ398/BYL719 in Solid TumorsCompletedNCT01928459Phase 1
- Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerActive, not recruitingNCT01872260Phase 1/2
- Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)CompletedNCT01822613Phase 1
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1
- PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric CancerCompletedNCT01613950Phase 1
- A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid TumorsCompletedNCT01449058Phase 1
- A Study of BYL719 in Adult Patients With Advanced Solid MalignanciesCompletedNCT01387321Phase 1
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast CancerCompletedNCT01300962Phase 1
- A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneCompletedNCT01219699Phase 1